Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer
Reid T. Powell(Texas A&M Health Science Center), Helen Piwnica‐Worms(Centre for Cancer Biology), Chunxiao Fu(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Xinhui Zhou(Zhejiang University), Shirong Cai(Sun Yat-sen University), Sabrina L. Jeter-Jones(The University of Texas MD Anderson Cancer Center), Amanda L. Rinkenbaugh(University of North Carolina at Chapel Hill), Clifford Stephan(Texas A&M Health Science Center), Peter J. Davies(IJ Research (United States)), Lei Guo(Second Military Medical University), Faiza Baameur Hancock(The University of Texas MD Anderson Cancer Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Yuan Qi(The University of Texas MD Anderson Cancer Center), Stacy Moulder(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Jiansu Shao(The University of Texas MD Anderson Cancer Center), Jeffrey T. Chang(Tufts University)
Cited by 11
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991